Mercola.com<\/p>\n
An investigative journalist looking at Pfizer\u2019s study protocols in its COVID-19 vaccine trials writes in The BMJ that a whistleblower who questioned the drug company\u2019s safety, data integrity and other trial practices was fired.<\/p>\n
\u201cSpeed may have come at the cost of data integrity and patient safety,\u201d says Paul D. Thacker, an American journalist specializing in science, medicine and environmental reporting.<\/p>\n
Thacker\u2019s allegations are not ones to be taken lightly: \u201cA regional director who was employed at the research organization Ventavia Research Group has told The BMJ that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer\u2019s pivotal Phase III trial,\u201d Thacker writes.<\/p>\n
Poor lab management, data integrity and patient safety concerns were major concerns, he says. Needles were improperly discarded, and vaccine packaging materials were left in the open with patient identification information clearly visible.<\/p>\n
Unblinding of the patient profiles and the drugs they received was also discovered in other ways, to the point that company officials couldn\u2019t \u201cquantify the types and number of errors they were finding,\u201d he says. Correct follow-up protocols with patients reporting severe adverse reactions weren\u2019t followed either.<\/p>\n
When an employee took photos of the missteps and reported the unsound practices to the FDA, she was fired. The FDA acknowledged her concerns \u2014 more than a dozen of them \u2014 but handed Pfizer an emergency use authorization (EUA) for the jab anyway, without mentioning the whistleblower\u2019s concerns.<\/p>\n
Speaking off the record, other employees confirmed that the fired employee\u2019s concerns were valid, with one confiding, \u201cI don\u2019t think it was clean data. It\u2019s a crazy mess.\u201d<\/p>\n